Publications

publicationpublibook


2017

  • Pro-differentiating effects of a synthetic flavagline on human teratocarcinomal cancer stem-like cells.
    Emhemmed F., Ali Azouaou S., Zhao Q., Appert-Collin A., Bennasroune A., Schini-Kerth V.B., Muller C.D., Désaubry L., Fuhrmann G.
    Cell Biol Toxicol.
    , 2017, ASAP

2016

  • A general and efficient synthesis of 2-pyridones, 2-quinolinones and 1-isoquinolinones from azine-N-oxides.
    Wang D., Zhao J., Wang Y., Hu J., Li L., Miao L., Feng H., Désaubry L;, Yu P.
    Asian J. Org. Chem.
    2016, 5, 1442-1446

  • Molecular pathways: the eIF4F translation initiation complex –new opportunities for cancer treatment.
    Malka-Mahieu H., Newman M., Désaubry L., Robert C., Vagner S.
    Clin Cancer Res.
    , 2016, 22, in press

  • Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
    Malka-Mahieu H., Girault I., Rubington M., Leriche M., Welsch C., Kamsu-Kom N., Zhao Q., Désaubry L., Vagner S., Robert C.
    Cell cycle
    , 2016, 15, 2405-2409

  • Synthesis of hydroxybenzofurans by condensation of quinones with benzoylacetone: revised structure of the adducts.
    Hammoud H., Zhao Q., Désaubry L. 
    Tetrahedron Lett., 2016,
    57, 4044–4045

  • Recent advances in the synthesis of flavaglines, a family of potent bioactive natural compounds coming from traditional Chinese medicine.
    Zhao Q., Abou-Hamdan H., Désaubry L.
    Eur. J. Org. Chem.
    , 2016, 5908-5916

  • STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A.
    Wang S, Darini C, Désaubry L, Koromilas AE.
    Mol Cancer Ther.
    , 2016,  15, 3055-3063

  • Bioisosteric modification of flavaglines
    Qian Z., Tijeras-Raballand A., de Gramont A., Raymond E., Désaubry L.
    Tetrahedron Lett.
    , 2016, 57, 2943

  • Flavaglines ameliorate experimental colitis and protect against intestinal epithelial cell apoptosis and mitochondrial dysfunction.
    Han J., Zhao Q., Basmadjian C., Désaubry L., Theiss A.L.
    Inflamm. Bowel Dis
    . 2016, 22, 55-67

 

 


2015

  • FL3, a synthetic flavagline and ligand of prohibitins, protects cardiomyocytes via STAT3 from doxorubicin toxicity.
    Qureshi R, Yildirim O, Gasser A, Basmadjian C, Zhao Q, Wilmet J-P, Désaubry L., Nebigil C.G.
    PLOS One
    2015, 10(11): e0141826.

  • Discovery and cardioprotective effects of the first non-peptide agonists of the G protein-coupled prokineticin receptor-1.
    Gasser A., Brogi S., Urayama K., Nishi T., Kurose H., Tafi A., Ribeiro N., Désaubry L., Nebigil CG.
    Plos One.
    2015, 10, e0121027

  • Revision of the synthesis and pharmacological activity of a reported translation inhibitor.
    Basmadjian C., Malka-Mahieu H., Désaubry L.
    Anticancer Agents Med. Chem.
    2015, 15, 1305-1307
  • Flavaglines stimulate transient receptor potential melastatin type 6 (TRPM6) channel activity.
    Blanchard MG., de Baaij J.H.F., Verkaart S.A.J., Lameris A.L., Basmadjian C., Zhao Q., Désaubry L., Bindels R.J.M., Hoenderop JG.
    Plos One 2015, 10, e0119028.
  • Assessment of flavaglines as potential chikungunya virus entry inhibitors.
    Wintachai, P.; Thuaud, F.; Basmadjian, C.; Ubol, S.; Désaubry, L.; Smith, D.R.
    Microbiol. Immunol. 2015, 59, 129-141

  • Exploratory studies toward a synthesis of flavaglines . A novel access to a highly substituted. cyclopentenone intermediate
    Basmadjian, C.; Zhao, Q.; Désaubry, L.
    Tetrahedron Lett.
    2015, 56, 727–730.


2014

  • eIF4F is a key and targetable convergence nexus of multiple resistance mechanisms to anti-RAF and anti-MEK cancer therapies.
    Boussemart, L.; Malka-Mahieu, H.; Girault, I.; Allard, D.; Hemmingsson, O.; Tomasic, G.; Thomas, M.; Basmadjian, C.; Ribeiro, N.; Thuaud, F.; Mateus, C.; Routier, E.; Kamsu-Kom, N.; Agoussi, S.; Eggermont, A. M.; Désaubry, L.; Robert, C.; Vagner, S.
    Nature 2014, 513, 105–109.

  • Benzofuran derivatives as anticancer inhibitors of mTOR signaling.
    Salomé, C.; Ribeiro, N.; Chavagnan, T.; Thuaud, F.; Serova, M.; de Gramont, A.; Faivre, S.; Raymond, E.; Désaubry, L.
    Eur. J. Med. Chem.
    2014, 81, 181–191.

  • Cancer wars: natural products strike back.
    Basmadjian, C.; Zhao, Q.; Bentouhami, E.; Djehal, A.; Nebigil, C. G.; Johnson, R. A.; Serova, M.; de Gramont, A.; Faivre, S.; Raymond, E.; Désaubry, L. G.
    Front. Chem.
    2014, 2, 20.

  • Selective anticancer effects of a synthetic flavagline on human Oct4-expressing cancer stem-like cells via a p38 MAPK-dependent caspase-3-dependent pathway.
    Emhemmed, F.; Ali Azouaou, S.; Thuaud, F.; Schini-Kerth, V.; Désaubry, L.; Muller, C. D.; Fuhrmann, G.
    Biochem. Pharmacol. 2014, 89, 185–196.

  • Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.
    Salomé, C.; Narbonne, V.; Ribeiro, N.; Thuaud, F.; Serova, M.; de Gramont, A.; Faivre, S.; Raymond, E.; Désaubry, L.
    Eur. J. Med. Chem.
    2014, 74, 41–49.


2013

  • N-[3a-(4-Bromophenyl)-8b-hydroxy-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta[b ]benzofuran-1-yl]formamide monohydrate.
    Aubert M., Thuaud F., Ribeiro N., Désaubry L., Espinosa E.
    Acta Cryst. E
     
    2013, 69, o52-o53
  • Prohibitin Ligands in Cell Death and Survival: Mode of Action and Therapeutic Potential,
    Thuaud F, Ribeiro N, Nebigil CG, Désaubry L.
    Chem Biol.
    2013, 20, 316-331

2012

  • Cytochromes P450 CYP94C1 and CYP94B3 catalyze two successive oxidation steps of plant hormone Jasmonoyl-isoleucine for catabolic turnover.
    Heitz, T.; Widemann, E.; Lugan, R.; Miesch, L.; Ullmann, P.; Désaubry, L.; Holder, E.; Grausem, B.; Kandel, S.; Miesch, M.; Werck-Reichhart, D.; Pinot, F.
    J. Biol. Chem.
    2012, 287, 6296–6306.
  • The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2.
    Polier, G.; Neumann, J.; Thuaud, F.; Ribeiro, N.; Gelhaus, C.; Schmidt, H.; Giaisi, M.; Köhler, R.; Müller, W. W.; Proksch, P.; Leippe, M.; Janssen, O.; Désaubry, L.; Krammer, P. H.; Li-Weber, M.
    Chem. Biol.
    2012, 19, 1093–1104.
  • Flavaglines as potent anticancer and cytoprotective agents.
    Ribeiro, N.; Thuaud, F.; Bernard, Y.; Gaiddon, C.; Cresteil, T.; Hild, A.; Hirsch, E. C.; Michel, P. P.; Nebigil, C. G.; Désaubry, L.
    J. Med. Chem.
    2012, 55, 10064–10073.

2011

  • Flavaglines Alleviate Doxorubicin Cardiotoxicity: Implication of Hsp27
    Bernard, Y.; Ribeiro, N.; Thuaud, F.; Türkeri, G.; Dirr, R.; Boulberdaa, M.; Nebigil, C.G.; Désaubry, L.; Saks, V.
    PLOS
    ONE
    2011, 6, e25302 (2011).

  • Identification of a low–molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice
    Cazorla, M.; Prémont, J.; MAnn, A.; Girard, N.; Kellendonk, C.; Rognan, Didier
    J. Clin. Invest. 2011, 121, 1846-1857